Citations

Clear

1526 citation(s) found for "Sun, Yu".

Abstract T P227: The Safety of Pioglitazone for Hematoma Resolution in IntraCerebral Hemorrhage (SHRINC) Trial: Safety Results
Gonzales, Nicole R. , Sangha, Navdeep , Kauffman, Teslyn, Cai, Chuyan, Sline, M. Rick, Pandurengan, Renga, Peng, Hui , Sosa, Lenis , Bowry, Ritvij , Prieto, Maria P, Hossain, Md. Monir , Kawano-Castillo, Jorge, Villamar, Gustavo D, Ofori, Kwami, Aramburo-Maldonado, Linda, Shen, Loren, Acosta, Indrani, Kasam, Mallikarjunarao , Wu, Tzu‐Ching , Sarraj, Amrou , Savitz, Sean I. , Rahbar, Mohammad H. , Zhao, Xiurong , Aronowski, Jaroslaw , Choi, Ellie E, Harun, Nusrat , Barreto, Andrew D. , Lopez, George, Ifejika, Nneka L. , Grotta, James C.

Mayo Clinic

Stroke | March 20, 2022 | Volume: 45 | Issue: suppl_1 | Pages: No page available

10.1161/str.45.suppl_1.tp227 Get It

Background and Objectives: Peroxisome proliferator activated receptor-gamma agonists, such as pioglitazone (PIO) enhanced hematoma resolution and improved functional recovery in our animal model of intracerebral hemorrhage (ICH). We conducted a translational Phase II randomized, controlled clinical trial to determine the maximum tolerated dose (MTD) of PIO in patients with spontaneous ICH and to explore the rate of hematoma resolution and clinical outcome. Methods: Patients with spontaneous ICH within 24 hours of symptom onset were randomly allocated 1:1 to placebo or PIO. Patients received escalating doses of PIO daily for three days, followed by a 30mg maintenance dose for the duration of treatment. Duration of treatment was when 75% of the ICH had resolved as determined by serial MRI or 10 weeks of treatment, whichever occurred first. The primary safety outcome was mortality at Day 14. Secondary measures of safety include any mortality, symptomatic cerebral edema, congestive heart failure, edema, hypoglycemia, anemia, and hepatotoxicity. Secondary measures of efficacy include hematoma resolution and clinical outcome. The MTD was determined using the Continual Reassessment Method. Results: From March 2009 to April 2013, 84 patients (42 PIO, 42 control) were enrolled into 11 dose tiers, with a planned range from 0.1-2.0 mg/kg/d. Table 1 demonstrates preliminary baseline and clinical characteristics of patients by treatment group. Overall, 2/84 patients died within 2 weeks after ICH; however mortality rate never exceeded prespecified criteria. The study will be complete in October 2013 and the treatment team remains blinded to treatment allocation. Secondary outcomes by treatment group and the MTD of PIO will be reported. Conclusions: We have completed the treatment phase of the SHRINC Trial. Long term follow-up is on-going. These results will provide the foundation for an efficacy trial evaluating PIO as a potential treatment for patients with spontaneous ICH.
Abstract P200: Transcriptional Regulation of tcap Conveys an Inhibitory Mechanotransductive Response to Modulate Cardiomyocyte Size
Yang, Jingchun , Sun, Xiaojing , Ding, Yonghe , Xu, Xiaolei

Mayo Clinic

Circulation Research | March 20, 2022 | Volume: 109 | Issue: suppl_1 | Pages: No page available

10.1161/res.109.suppl_1.ap200 Get It

To sense and to respond to mechanical stimuli is a fundamental process of cardiomyocytes during both heart development and diseases. However, how mechanical stimuli control cardiomyocyte size remains elusive. Here, we report a novel inhibitory mechanotransductive response suggested by loss-of-functions studies of α-Actinin2 (Actn2), a predominant sarcomeric Z-disc protein. During zebrafish cardiogenesis, depletion of Actn2 results in a defective Z-disc, while other sarcomeric substructures remain normal. As a consequence, ventricle chamber size is severely reduced. Interestingly, this chamber size reduction can be rescued by the cessation of heart contraction, suggesting the involvement of an inhibitory mechanotransductive reponse. At the molecular level, both tcapa and tcapb, two zebrafish tcap homologues that are transcriptionally responsive to stretch, are transcriptionally activated in actn2 knockdown embryos while activation of these gene results in smaller cardiomyocytes. Depletion of either gene rescues the reduced cardiomyocyte size in actn2 knockdown embryos. Consistent to embryonic studies, tcaps are transcriptionally activated during pathogenesis of anemia-induced cardiomyopathy, while over expression of tcapa via transgenics exerts a cardioprotective effect. Together, we conclude that transcriptional regulation of tcaps conveys a novel inhibitory mechanotransductive response that modulates cardiomyocyte size during both zebrafish cardiogenesis and adult cardiac remodeling.
Abstract 283: Association of Body Mass Index with Outcomes in Patients with Atrial Fibrillation: Results From the ORBIT-AF Registry
Shrader, Peter, Thomas, Laine , Kowey, Peter R. , Sun, Shining, Burton, Paul , Piccini, Jonathan P. , Pandey, Ambarish , Gersh, Bernard J. , McGuire, Darren K. , Mahaffey, Kenneth W. , Hylek, Elaine M. , Peterson, Eric D. , Fonarow, Gregg C.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 8 | Issue: suppl_2 | Pages: No page available

10.1161/circoutcomes.8.suppl_2.283 Get It

Introduction: Higher body mass index (BMI) is an independent risk factor for incident atrial fibrillation (AF). However, its impact on management strategies and clinical outcomes among patients with prevalent AF is unclear. Methods: The study cohort included patients with AF enrolled in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry from June 2010 through August 2011. Participants with BMI > 18.5 kg/m2 were stratified into normal (18.5 - 25 kg/m2), overweight (25 - 30 kg/m2), Class I obese (30 - 35 kg/m2), Class II obese (35 - 40 kg/m2), and Class III obese (>40 kg/m2) categories. Unadjusted and adjusted Cox frailty models were constructed to assess the categorical and continuous association of BMI with AF progression, mortality, and incidence of thromboembolic events. Results: We evaluated 9,606 patients with AF (mean age: 74 + 11 years; 42% women) from 174 US ORBIT participating practices. Patients in the higher BMI categories were younger and had a higher prevalence of comorbidities such as diabetes, hypertension, and obstructive sleep apnea. AF symptom burden was greatest among patients in extreme BMI categories. Proportional use of anticoagulation, antiarrhythmic drugs, and invasive rhythm control strategies was significantly greater among patients in higher BMI categories. Rates for mortality and stroke/non-CNS embolism decreased in a near linear fashion across successively higher BMI categories (P<0.001; Table). After multivariable adjustment, higher BMI categories were associated with lower risk for mortality (p = 0.0002), with the lowest risk observed among overweight patients [Hazard Ratio (HR) (95% CI): 0.65 (0.54 - 0.79) ref. group: normal weight]. For every 5-kg/m2 increase in BMI, the odds of risk-adjusted mortality were 6% lower [HR (95% CI): 0.94 (0.89 - 0.98)]. In contrast, the association between BMI and risk for stroke/non-CNS embolism was significant on unadjusted analysis (P <0.001) but attenuated after adjustment for risk factors (P = 0.78; Table). No significant association was observed between BMI and AF progression rates in either unadjusted (P = 0.35) or adjusted analyses (P = 0.17). Conclusion: Among patients with AF, higher BMI was associated with a greater use of anticoagulation, rhythm control strategies, and lower mortality risk.
Abstract MP34: Association of Overweight and Obesity with an Incidence of Heart Failure: A Systematic Review and Meta-analysis
Krittanawong, Chayakrit , Tunhasiriwet, Anusith, Zhang, Hongju , Prokop, Larry J. , Tweet, Marysia S. , Chirapongsathorn, Sakkarin , Wang, Zhen , Sun, Tao, Hayes, Sharonne N.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 133 | Issue: suppl_1 | Pages: No page available

10.1161/circ.133.suppl_1.mp34 Get It

Introduction: Obesity is a growing global health problem associated with substantial morbidity and mortality. The risk of obesity on incident new-onset heart failure is controversial. The aim of this systematic review and meta-analysis was to explore the association between overweight, obesity and incident new-onset heart failure. Methods: We systematically searched MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Scopus, and the Cochrane Central Register of Controlled Trials from database inception through April 2015. Prospective cohort studies were included if the studies reported hazard ratios (HRs) of the association between overweight or obesity and new-onset heart failure (HF) relative to individuals with normal weight. Data were extracted by one reviewer followed by independent screening and extraction of study characteristics and outcome data by two other reviewers. Conflicts were resolved through consensus. Random-effects meta-analyses were used to pool the hazard ratio from the included studies. Subgroup analyses were performed to explore the potential sources of heterogeneity. Results: Out of 1,865 retrieved articles, we identified 10 relevant studies. Median follow-up was 12 years with a total of 82,167 individuals and 4,570 total HF events. Compared to normal body weight (body mass index (BMI) <25 kg/m2), overweight (BMI 25-29.9 kg/m2) was associated with 27% higher risk of new-onset heart failure events (pooled HR, 1.27; 95% confidence intervals (95% CI): 1.15-1.41; p<0.001; I 2 = 0%) and obesity (BMI ≥30 kg/m2) was associated with a two-fold increased risk for new-onset heart failure events (pooled HR, 2.09; 95% CI, 1.68-2.60; p<0.001; I 2 = 67.8%). Conclusions: Compared with normal-weight individuals, both overweight and obesity were independently associated with significantly higher incidence of heart failure. These results highlight the need for better understanding of mechanisms of obesity and heart failure.
Allergic airway recall responses require IL-9 from resident memory CD4 + T cells
Ulrich, Benjamin J. , Kharwadkar, Rakshin , Chu, Michelle , Pajulas, Abigail , Muralidharan, Charanya , Koh, Byunghee , Fu, Yongyao , Gao, Hongyu , Hayes, Tristan , Zhou, Hongming , Goplen, Nick P., Nelson, Andrew S. , Turner, Matthew J. , Licona-Limón, Paula , Kaplan, Mark H. , Hayes, Tristan A , Zhou, Hong-Ming , Goplen, Nicholas P , Liu, Yunlong , Linnemann, Amelia K , Turner, Matthew J , Licona-Limón, Paula , Flavell, Richard A , Sun, Jie , Kaplan, Mark H , Flavell, Richard A. , Sun, Jie

Mayo Clinic

Science Immunology | March 18, 2022 | Volume: 7 | Issue: 69 | Pages: No page available

10.1126/sciimmunol.abg9296 | PMID 35302861 Get It

Asthma is a chronic inflammatory lung disease with intermittent flares predominately mediated through memory T cells. Yet, the identity of long-term memory cells that mediate allergic recall responses is not well defined. In this report, using a mouse model of chronic allergen exposure followed by an allergen-free rest period, we characterized a subpopulation of CD4 + T cells that secreted IL-9 as an obligate effector cytokine. IL-9–secreting cells had a resident memory T cell phenotype, and blocking IL-9 during a recall challenge or deleting IL-9 from T cells significantly diminished airway inflammation and airway hyperreactivity. T cells secreted IL-9 in an allergen recall–specific manner, and secretion was amplified by IL-33. Using scRNA-seq and scATAC-seq, we defined the cellular identity of a distinct population of T cells with a proallergic cytokine pattern. Thus, in a recall model of allergic airway inflammation, IL-9 secretion from a multicytokine-producing CD4 + T cell population was required for an allergen recall response.
Mitochondrial pyruvate carrier-mediated metabolism is dispensable for the classical activation of macrophages
Ran, Linyu, Zhang, Song , Zhao, Pei , Sun, Jiaxing , Gan, Haiyun , Li, Qiang , Herrmann, Joerg , Zhang, Song , Ran, Linyu, Zhou, Jiaqi, Jeon, Ryoung‐Hoon , Wang, Feilong

Mayo Clinic

No container title available | March 10, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1413776/v1 Get It

Abstract Glycolysis is essential for the classical activation of macrophages (M1), but how glycolytic pathway metabolites engage in this process remains to be elucidated. Glycolysis culminates in the production of pyruvate, which can be transported into the mitochondria by the mitochondrial pyruvate carrier (MPC) followed by conversion to citrate and utilization in the TCA cycle. Alternatively, pyruvate can be metabolized to lactate under aerobic conditions, which had been considered to be the dominant route in the setting of classical macrophage activation. However, based on studies that used UK5099 as a MPC inhibitor and showed reduction in key inflammatory cytokines, the mitochondrial route has been considered to be of significance for M1 activation as well. Herein, using a genetic depletion model, we found that MPC is dispensable for metabolic reprogramming and the activation of M1. In addition, MPC depletion in myeloid cells has no impact on inflammatory responses and macrophage polarization toward M1 phenotype in the endotoxemia mice model. While UK5099 reaches maximal MPC inhibitory capacity at approximately 2–5µM, higher concentrations are required to inhibit inflammatory cytokine production in M1 and this is independent of MPC expression. Taken together, this study found MPC-mediated metabolism is dispensable for the classical activation of macrophages, and UK5099 inhibits inflammatory responses in M1 macrophages due to effects other than MPC inhibition.
Large-scale Integrated Analysis of Genetics and Metabolomic Data Reveals Potential Links Between Lipids and Colorectal Cancer Risk
Shu, Xiao-Ou , Chen, Zhishan, Long, Jirong, Guo, Xingyi, Yang, Yaohua , Qu, Conghui, Ahn, Yoon-Ok, Cai, Qiuyin , Casey, Graham, Gruber, Stephen B. , Huyghe, Jeroen R. , Jee, Sun Ha, Jenkins, Mark A., Jia, Wei-Hua, Jung, Keum Ji, Kamatani, Yoichiro, Kim, Dong-Hyun, Marchand, Loic Le, Newcomb, Polly A., Oh, Jae Hwan, Ose, Jennifer , Pai, Rish K. , Pan, Zhi-Zhong, Ren, Ze-Fang, Shin, Aesun, Sun, Xiaohui, Tangen, Catherine M., Tanikawa, Chizu, Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Woods, Michael O. , Wu, Anna H., Peters, Ulrike , Jee, Sun Ha , Chen, Zhishan , Shu, Xiao-Ou , Kim, Jeongseon , Kweon, Sun-Seog , Matsuda, Koichi , Matsuo, Keitaro , Ose, Jennifer , Oze, Isao , Pai, R K , Pharoah, Paul D P , Playdon, Mary C , Schoen, Robert E , Shin, Min‐Ho , Shu, Xiao-Ou , Ulrich, Cornelia M , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Wolk, Alicja , Woods, Michael O , Peters, Ulrike , Zheng, Wei , Gruber, Stephen B , Cai, Qiuyin , Chen, Zhishan, Long, Jirong, Guo, Xingyi, Yang, Yaohua , Qu, Conghui, Ahn, Yoon-Ok, Casey, Graham, Huyghe, Jeroen R , Jenkins, Mark A., Jia, Wei-Hua, Jung, Keum Ji, Kamatani, Yoichiro, Kim, Dong-Hyun, Marchand, Loic Le, Newcomb, Polly A., Oh, Jae Hwan, Pan, Zhi-Zhong, Ren, Ze-Fang, Shin, Aesun, Sun, Xiaohui, Tangen, Catherine M., Tanikawa, Chizu, Wu, Anna H.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 10, 2022 | Volume: 31 | Issue: 6 | Pages: 1216-1226

10.1158/1055-9965.epi-21-1008 | PMID 35266989 Get It

Abstract Background: The etiology of colorectal cancer is not fully understood. Methods: Using genetic variants and metabolomics data including 217 metabolites from the Framingham Heart Study (n = 1,357), we built genetic prediction models for circulating metabolites. Models with prediction R2 &gt; 0.01 (Nmetabolite = 58) were applied to predict levels of metabolites in two large consortia with a combined sample size of approximately 46,300 cases and 59,200 controls of European and approximately 21,700 cases and 47,400 controls of East Asian (EA) descent. Genetically predicted levels of metabolites were evaluated for their associations with colorectal cancer risk in logistic regressions within each racial group, after which the results were combined by meta-analysis. Results: Of the 58 metabolites tested, 24 metabolites were significantly associated with colorectal cancer risk [Benjamini–Hochberg FDR (BH-FDR) &lt; 0.05] in the European population (ORs ranged from 0.91 to 1.06; P values ranged from 0.02 to 6.4 × 10−8). Twenty one of the 24 associations were replicated in the EA population (ORs ranged from 0.26 to 1.69, BH-FDR &lt; 0.05). In addition, the genetically predicted levels of C16:0 cholesteryl ester was significantly associated with colorectal cancer risk in the EA population only (OREA: 1.94, 95% CI, 1.60−2.36, P = 2.6 × 10−11; OREUR: 1.01, 95% CI, 0.99−1.04, P = 0.3). Nineteen of the 25 metabolites were glycerophospholipids and triacylglycerols (TAG). Eighteen associations exhibited significant heterogeneity between the two racial groups (PEUR-EA-Het &lt; 0.005), which were more strongly associated in the EA population. This integrative study suggested a potential role of lipids, especially certain glycerophospholipids and TAGs, in the etiology of colorectal cancer. Conclusions: This study identified potential novel risk biomarkers for colorectal cancer by integrating genetics and circulating metabolomics data. Impact: The identified metabolites could be developed into new tools for risk assessment of colorectal cancer in both European and EA populations.
Abstract P5-13-21: Relationship between circulating tumor DNA and response to neoadjuvant niraparib in HER2-negative, BRCA-mutated breast cancer
Shan, Ming , Liu, Minetta C. , Santa‐Maria, Cesar A. , Isakoff, Steven J. , Reeves, James E., Ellisen, Leif W. , Lim, Lee P. , Garg, Kavita S. , Bertucci, Caterina, Feng, Bin , Sun, Kaiming, Graham, Julie R. , Hofstatter, Erin, Spring, Laura , Hamilton, Erika , Irie, Hanna Y. , Santa-Maria, Cesar Augusto , Zhang, Hailei , Sun, Kaiming , Han, Hyo S

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: P5-13-21-P5-13-21

10.1158/1538-7445.sabcs21-p5-13-21 Get It

Abstract Background: Survival advantages with neoadjuvant chemotherapy (NACT) have been observed in patients (pts) with locally advanced breast cancer (BC) who achieve pathological complete response (pCR). Predicting risk of early recurrence in pts without pCR remains difficult. Circulating tumor DNA (ctDNA) may be a biomarker of neoadjuvant therapy response and recurrence. This study applied tumor genotyping of peripheral blood in pts with HER2− tumor BRCA-mutated (tBRCAm) BC treated with neoadjuvant niraparib. The relationship between ctDNA and tumor response was also characterized, with a focus on circulating TP53 mutant allelic frequency (MAF). Methods: Blood was collected from 21 pts enrolled in the study (NCT03329937) evaluating neoadjuvant niraparib in pts with localized HER2− tBRCAm BC. Pts received niraparib 200 mg once daily for two 28-day cycles. After 2 cycles, pts underwent surgery or received up to 6 cycles of niraparib and/or NACT prior to surgery. Blood samples were collected at screening, Cycle 1 Day 28 (C1D28), Cycle 2 Day 28 (C2D28), and pre-surgery. Ultrasound (USG) was done after each cycle and MRI after Cycle 2. Next-generation sequencing of cell-free plasma DNA was carried out using a proprietary target capture and analysis (Paweletz, Clin Cancer Res 2016). Results: ctDNA and TP53 mutations (TP53m) were detected at screening in 10/21 pts (47.6%). Across all 21 pts there was a correlation between TP53 MAF and baseline tumor stage (T) (mean [standard deviation], T1 0 [0], T2 0.05 [0.09], and T3 0.21 [0.12]; P=0.005). Linear regression modelling showed a positive correlation between tumor volume and baseline TP53 MAF (R2=0.206, P=0.0386). Baseline TP53 MAF also appeared to be associated with advanced disease stage (Table 1). Depletion of detectable TP53m from baseline was evident by C1D28 and persisted to pre-surgery (Table 2). This corresponded with decreases in tumor volume at C1D28 and further decreases at C2D28. Of 11 pts analyzed, 6 pts with &gt;90% tumor volume decreases by MRI or USG at C2D28 had sustained TP53m depletion. Three pts had pCR; of these, 2 had sustained TP53m depletion (data unavailable for third pCR pt). Two pts with less robust tumor responses had increased pre-surgery TP53 MAF. Conclusions: We report the potential utility of ctDNA as a predictive biomarker for neoadjuvant niraparib response in pts with HER2− tBRCAm BC. Although sample size limited analysis of genes other than TP53, baseline ctDNA strongly correlated with tumor volume, and TP53 MAF was associated with tumor volume and trended towards association with disease stage. Longitudinal analysis of TP53 MAF suggested a correlation with niraparib response. Further study of ctDNA dynamics during NACT and correlation with pCR and long-term clinical outcomes is warranted. Funding: GlaxoSmithKline (GSK) study 213355; NCT03329937. Medical writing support was provided by Fishawack Indicia, part of Fishawack Health, funded by GSK. Table 1.Baseline TP53 MAF association with disease stage and subtypeTP53 MAFDisease Stage (I–III)Disease SubtypeStage IStage IIStage IIIHR+TNBC(n=8)(n=10)(n=3)(n=6)(n=15)Mean (SD)0.01 (0.02)0.07 (0.12)0.10 (0.05)0.02 (0.02)0.06 (0.10)HR, hormone receptor; MAF, mutant allelic frequency; SD, standard deviation; TNBC, triple-negative breast cancer. Table 2.TP53 MAF correlation with tumor volume decrease by ultrasound and MRIOutcomeScreeningCycle 1 Day 28 Cycle 2 Day 28 Pre-Surgeryn11997TP53 MAF, mean, (SD)0.09 (0.11)000.01 (0.02)n11112Percent change in tumor volume from baseline by MRI, mean (SD)-N/A*−72.6 (22.5)N/A*Percent change in tumor volume from baseline by ultrasound, mean (SD)-−60.8 (24.0)−80.6 (21.8)−95.9 (4.3)*MRI was only performed at Cycle 2 Day 28. MAF, mutant allelic frequency; MRI, magnetic resonance imaging; N/A, not applicable; SD, standard deviation. Citation Format: Ming Shan, Laura Spring, Minetta C Liu, Erika Hamilton, Hanna Irie, Cesar A Santa-Maria, Steven J Isakoff, James Reeves, Leif W Ellisen, Lee P Lim, Kavita Garg, Caterina Bertucci, Bin Feng, Hailei Zhang, Kaiming Sun, Julie R Graham, Erin Hofstatter, Hyo Han. Relationship between circulating tumor DNA and response to neoadjuvant niraparib in HER2-negative, BRCA-mutated breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-13-21.
Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer
Zhang, Yixiao, Sun, Lisha , Li, Haonan, Ai, Liping, Ma, Qingtian, Qiao, Xinbo , Yang, Jie, Zhang, Hao, Ou, Xunyan, Wang, Yining, Chen, Guanglei, Xue, Jinqi, Zhu, Xudong, Zhao, Yu, Yang, Yongliang, Liu, Caigang , Zhu, Xudong , Zhang, Yixiao, Sun, Lisha , Li, Haonan, Ai, Liping, Ma, Qingtian, Qiao, Xinbo , Yang, Jie, Zhang, Hao, Ou, Xunyan, Wang, Yining, Chen, Guanglei, Xue, Jinqi, Zhu, Xudong, Zhao, Yu, Yang, Yongliang, Liu, Caigang

Mayo Clinic

eLife | March 8, 2022 | Volume: 11 | Issue: No issue available | Pages: No page available

10.7554/elife.68481 | PMID 35285795 Get It

Background: Integrin family are known as key gears in focal adhesion for triple-negative breast cancer (TNBC) metastasis. However, the integrin independent factor TLN1 remains vague in TNBC. Methods: Bioinformatics analysis was performed based on TCGA database and Shengjing Hospital cohort. Western blot and RT-PCR were used to detect the expression of TLN1 and integrin pathway in cells. A small-molecule C67399 was screened for blocking TLN1 and integrin β1 through a novel computational screening approach by targeting the protein-protein binding interface. Drug pharmacodynamics were determined through xenograft assay. Results: Upregulation of TLN1 in TNBC samples correlates with metastasis and worse prognosis. Silencing TLN1 in TNBC cells significantly attenuated the migration of tumour cells through interfering the dynamic formation of focal adhesion with integrin β1, thus regulating FAK-AKT signal pathway and epithelial-mesenchymal transformation. Targeting the binding between TLN1 and integrin β1 by C67399 could repress metastasis of TNBC. Conclusions: TLN1 overexpression contributes to TNBC metastasis and C67399 targeting TLN1 may hold promise for TNBC treatment. Funding: This study was supported by grants from the National Natural Science Foundation of China (No. 81872159, 81902607, 81874301), Liaoning Colleges Innovative Talent Support Program (Name: Cancer Stem Cell Origin and Biological Behaviour), Outstanding Scientific Fund of Shengjing Hospital (201803), and Outstanding Young Scholars of Liaoning Province (2019-YQ-10).
An IL-9–pulmonary macrophage axis defines the allergic lung inflammatory environment
Fu, Yongyao , Wang, Jocelyn , Zhou, Baohua , Pajulas, Abigail , Gao, Hongyu , Ramdas, Baskar , Koh, Byunghee , Ulrich, Benjamin J. , Yang, Shuangshuang , Kapur, Reuben , Licona-Limón, Paula , Takatsuka, Shogo , Kitamura, Daisuke , Kaplan, Mark H. , Renauld, Jean-Christophe , Paczesny, Sophie , Liu, Yunlong , Tighe, Robert M , Licona-Limón, Paula , Flavell, Richard A , Takatsuka, Shogo , Tepper, Robert S , Sun, Jie , Kaplan, Mark H , Tighe, Robert M. , Flavell, Richard A. , Sun, Jie

Mayo Clinic

Science Immunology | February 18, 2022 | Volume: 7 | Issue: 68 | Pages: No page available

10.1126/sciimmunol.abi9768 | PMID 35179949 Get It

Despite IL-9 functioning as a pleiotropic cytokine in mucosal environments, the IL-9–responsive cell repertoire is still not well defined. Here, we found that IL-9 mediates proallergic activities in the lungs by targeting lung macrophages. IL-9 inhibits alveolar macrophage expansion and promotes recruitment of monocytes that develop into CD11c + and CD11c − interstitial macrophage populations. Interstitial macrophages were required for IL-9–dependent allergic responses. Mechanistically, IL-9 affected the function of lung macrophages by inducing Arg1 activity. Compared with Arg1-deficient lung macrophages, Arg1-expressing macrophages expressed greater amounts of CCL5. Adoptive transfer of Arg1 + lung macrophages but not Arg1 − lung macrophages promoted allergic inflammation that Il9r −/− mice were protected against. In parallel, the elevated expression of IL-9, IL-9R, Arg1, and CCL5 was correlated with disease in patients with asthma. Thus, our study uncovers an IL-9/macrophage/Arg1 axis as a potential therapeutic target for allergic airway inflammation.